Search Results for "Alnylam"
Alnylam is committed to providing the healthcare community with balanced, accurate, and high-quality information about our science, therapeutic areas, and products.
More than one search term is recommended to yield the most relevant results. By searching, you confirm that your query is unsolicited.
For more information about our FDA-approved therapies, please see the Full Prescribing Information:
Patisiran: Preparation and Administration
Standard response letter on the preparation and administration of patisiran.
Standard response letter on the preparation and administration of patisiran.
Patisiran: Management of Infusion-Related Reactions
Standard response letter on the management of infusion-related reactions in patisiran clinical studies.
Standard response letter on the management of infusion-related reactions in patisiran clinical studies.
Efficacy and Safety of Vutrisiran and Patisiran
Standard response letter on the efficacy and safety of vutrisiran and patisiran, summarizing data from the HELIOS-A study and the APOLLO study.
Standard response letter on the efficacy and safety of vutrisiran and patisiran, summarizing data from the HELIOS-A study and the APOLLO study.
Givosiran: Use in Pediatric Patients
Standard response letter on givosiran and pediatric use. This medical information response contains clinical data from the ENVISION study, ELEVATE registry, and published case reports.
Standard response letter on givosiran and pediatric use. This medical information response contains clinical data from the ENVISION study, ELEVATE registry, and published case reports.
Vutrisiran: Transitioning from Antisense Oligonucleotide
Standard response letter on transitioning from an antisense oligonucleotide to vutrisiran.
Standard response letter on transitioning from an antisense oligonucleotide to vutrisiran.
Vutrisiran: Cardiac Results from the HELIOS-A Study
Standard response letter on vutrisiran and exploratory cardiac results from the HELIOS-A study evaluating efficacy and safety of vutrisiran in patients with polyneuropathy of hATTR.
Standard response letter on vutrisiran and exploratory cardiac results from the HELIOS-A study evaluating efficacy and safety of vutrisiran in patients with polyneuropathy of hATTR.